BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27222706)

  • 21. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
    Yan L; Elkassar N; Gardin C; Briere J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of chronic myeloproliferative neoplasias in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
    Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.
    Abdelouahab H; Zhang Y; Wittner M; Oishi S; Fujii N; Besancenot R; Plo I; Ribrag V; Solary E; Vainchenker W; Barosi G; Louache F
    Oncotarget; 2017 Aug; 8(33):54082-54095. PubMed ID: 28903325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.
    Li Y; Hetet G; Kiladjian JJ; Gardin C; Grandchamp B; Briere J
    Br J Haematol; 1996 Jan; 92(1):60-6. PubMed ID: 8562412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
    Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
    Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Elsayed AG; Ranavaya A; Jamil MO
    Hematol Rep; 2019 Feb; 11(1):7868. PubMed ID: 30996850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.
    Gonzalez-Villalva A; Piñon-Zarate G; Falcon-Rodriguez C; Lopez-Valdez N; Bizarro-Nevares P; Rojas-Lemus M; Rendon-Huerta E; Colin-Barenque L; Fortoul TI
    Toxicol Ind Health; 2016 May; 32(5):908-18. PubMed ID: 24442345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes.
    Fu C; Hu X; Wang S; Yu X; Zhang Q; Zhang L; Qi K; Li Z; Xu K
    Exp Hematol; 2023 Nov; 127():59-69.e2. PubMed ID: 37741606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in understanding myelofibrosis and essential thrombocythemia.
    Vainchenker W; Constantinescu SN; Plo I
    F1000Res; 2016; 5():. PubMed ID: 27134742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways.
    Doshi PD; Giri JG; Abegg AL; Favara JP; Huynh MS; Kahn LE; Minnerly JC; Pegg LE; Villani-Price D; Siegel NR; Staten NR; Thomas JW; McKearn JP; Smith WG
    Exp Hematol; 2001 Oct; 29(10):1177-84. PubMed ID: 11602319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
    Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells.
    Kwiatkowski BA; Burwick NR; Richard RE
    Biomark Res; 2019; 7():13. PubMed ID: 31321035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare
    Langabeer SE; Lee Tokar L; Kearney L; O'Brien C; Thavarajah K; Barrett A; McManus J; O'Leary H
    Case Rep Hematol; 2020; 2020():8375986. PubMed ID: 32637179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
    Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
    Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.